4D Molecular Therapeutics Inc (NASDAQ: FDMT) on Monday, plunged -5.97% from the previous trading day, before settling in for the closing price of $16.09. Within the past 52 weeks, FDMT’s price has moved between $9.44 and $36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 111.29%. The company achieved an average annual earnings per share of -10.49%. With a float of $43.53 million, this company’s outstanding shares have now reached $51.70 million.
Let’s determine the extent of company efficiency that accounts for 147 employees.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of 4D Molecular Therapeutics Inc is 15.80%, while institutional ownership is 104.45%. The most recent insider transaction that took place on Jul 16 ’24, was worth 47,442. In this transaction Chief Legal Officer of this company sold 1,750 shares at a rate of $27.11, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Jul 11 ’24, when Company’s Chief Legal Officer sold 1,996 for $25.00, making the entire transaction worth $49,900. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
As on 3/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.77 earnings per share (EPS) for the period topping the consensus outlook (set at -0.81) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.49% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
4D Molecular Therapeutics Inc (FDMT) is currently performing well based on its current performance indicators. A quick ratio of 32.65 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -3.21 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Looking closely at 4D Molecular Therapeutics Inc (NASDAQ: FDMT), its last 5-days average volume was 0.49 million, which is a drop from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 26.45%. Additionally, its Average True Range was 1.82.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 4.43%, which indicates a significant decrease from 6.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 192.31% in the past 14 days, which was higher than the 97.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.68, while its 200-day Moving Average is $21.63. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $15.61. Second resistance stands at $16.09. The third major resistance level sits at $16.75. If the price goes on to break the first support level at $14.47, it is likely to go to the next support level at $13.81. Now, if the price goes above the second support level, the third support stands at $13.33.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
Market capitalization of the company is 782.22 million based on 51,703K outstanding shares. Right now, sales total 20,720 K and income totals -100,840 K. The company made 30 K in profit during its latest quarter, and -32,400 K in sales during its previous quarter.
